Home > Boards > US OTC > Cannabis >

Greater Cannabis Company Inc. (GCAN)

GCAN RSS Feed
Add GCAN Price Alert      Hide Sticky   Hide Intro
Moderator: Sprycel, Fuzzy Bunny, abe01, Dr. Gwinis, KANEMAN, downandoutthanksd
Search This Board: 
Last Post: 10/22/2019 12:19:24 AM - Followers: 195 - Board type: Free - Posts Today: 1



https://www.healtheuropa.eu/symtomax-the-medical-cannabis-company-leading-the-field/94127/

October 17, 2019

Symtomax are at the forefront to offer cheaper production, providing products at the certification grade Europe requires. With current demand outstripping supply in the European Union, it’s easy to see why Symtomax are confident about how they have positioned themselves. Symtomax’s vision and strategic direction is evident in the recently announced partnership. In May of this year Symtomax and Greater Cannabis Company a publicly traded biopharmaceutical, based out of Baltimore, with a focus on the development and commercialisation of cannabinoid delivery systems, signed a joint agreement giving rights to use their tested patented delivery products & distribution throughout Europe, Middle East and Africa.

With concern growing over vaping and the numerous incidents now being reported, Symtomax’s new oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.

This new Innovative delivery system using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, provides for a needle free, intra-oral systemic drug delivery.

Paul Segal, Chairman said: “Our focus has always been on providing safe, accessible, alternative medicines, with patients and consumers demanding safer routes of administration, while achieving proper potency and higher bioavailability, we believe we can now meet this need as well as the expectations.”

Symtomax have established sales and distribution arrangements to supply their cannabinoid-containing products through major pharmaceutical distribution channels throughout Portugal and the European Union (EU). The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration




MEET THE GCANRX DREAM TEAM:
     
            Aitain Zacharin, CEO                   Mark Randon, Esquire / General Counsel       David Tavor, Board of Directors                       Dr. Hock S. Tan, PHD        

  
____Fernando Bisker, Partner                                                                            Elisha Kalfa_______

“By improving the bioavailability of cannabinoids molecules we can deliver lower doses of actives while achieving greater therapeutic efficacy.”

- Aitan Zacharin, CEO of GCANRx
http://www.gcanrx.com

VIEW THE GCAN CEO INTERVIEW ON CHEDDAR TV
https://cheddar.com/media/gcanrx-offers-an-adjustable-and-dissolvable-cannabis-patch

View the GCAN CEO INTERVIEW ON CEO MONEY - Episode 28
https://www.youtube.com/watch?v=ZwI48a46KjI&feature=youtu.be


 SHARE STRUCTURE AS OF OCTOBER 18,  2019 CONFIRMED BY T/A
500,000,000 Authorized Common Shares
35,447,483 Total Outstanding Common Shares
16,635,945 Total Restricted Common Shares


https://www.otcmarkets.com/stock/GCAN/security

Transfer Agent contact information:

Luke Chakmakdjia
Client Services Representative
Pacific Stock Transfer
702-361-3033 Ext 111 Phone
800-785-7782 Toll Free Phone
702-433-1979 Fax

 
Since the first shares of 26,905,959 shares were issued and with the current reported shares being 35,447,483, an increase of just 8,641,524  shares, the traded volume of the common stock since the first day of trading being Sept 18, 2018, has been exactly 108,635,530 shares up to and including October 21, 2019.  (https://finance.yahoo.com/quote/GCAN/history?p=GCAN 

Preferred A shares--9,411,998 shares are owned by the following people who are all insiders of GCAN and were all issued on July 31, 2018 per the SEC filing:

Elisha Kalfa and Yonah Kalfa own 2,966,666 shares
Fernando Bisker and Sigalush LLC own 2,966,666 shares
Aitan Zacharin owns 1,695,333 shares
Mark Randon owns 1,483,333 shares
David Tavor owns 300,000 shares

Each Preferred A share is subject to a 50 for 1 conversion to common stock from their issue date of July 31, 2018 EXCEPT 5,933,332 convertible preferred A shares which can not be touched for 18 months from July 31, 2018. See Page F-12 on the 10Q for clarification.  Not one Preferred A Share has been converted as of October 18, 2019. 

Preferred B Shares--9,000,000 shares issued to EMET CAPITAL on February 14, 2019. Each share is subject to a 1 to 1 conversion to common stock from their issue date of February 14, 2019 If fully converted these Preferred B shares would require 9,000,000 common shares at no set price so whatever the street value is at time of conversion is what EMET would get. 
  Not one Preferred B share has been converted as of  October 18, 2019

ALSO IT IS VERY IMPORTANT TO UNDERSTAND THE ONLY DEBT CURRENTLY ON THE BOOKS AT GCAN AND ARE AS FOLLOWS PER THE COMPANY'S SEC FILINGS:

(vi) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”) having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. The Eagle Note is to mature one year from the Issue Date. Eagle is to fund the $1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $250,000 was received by the Company on February 13, 2019.

The Eagle Note may be pre-paid in whole or in part by paying Eagle the following premiums:

PREPAY DATE PREPAY AMOUNT
= 30 days 105% * (Principal + Interest (“P+I”)
31- 60 days 110% * (P+I)
61-90 days 115% * (P+I)
91-120 days 120% * (P+I)
121-150 days 125% * (P+I)
151-180 days 130% * (P+I)

Any amount of principal or interest on the Eagle Note, which is not paid when due shall bear interest at the rate of twenty four (24%) per annum from the due date thereof until the same is paid (“Default Interest”).

Eagle has the right beginning on the date which is one hundred eighty (180) days following the Issue Date (AUGUST 12TH, 2019) to convert all or any part of the outstanding and unpaid principal amount of the Eagle Note into fully paid and non-assessable shares of common stock of the Company at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 65% of the lowest closing price of the Company’s common stock as reported on the National Quotations Bureau OTC Market exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future (“Exchange”), for the fifteen prior trading days including the day upon which a Notice of Conversion is received by the Company. The Eagle Note contains other customary terms found in like instruments for conversion price adjustments.
As of October 18, 2019  EAGLE has not converted one penny of debt into common stock.  

Here is another very important link for review and it is the Florida SOS link:

http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=GREATERCANNABIS%20P170000045370&aggregateId=domp-p17000004537-69a1f1d7-2049-4ebf-bb2d-ecbb1559d26b&searchTerm=greater%20cannabis&listNameOrder=GREATERCANNABIS%20L140000462060





 

 
http://greatercannabiscompany.com

The Greater Cannabis Company, Inc.

Contact us

THE GREATER CANNABIS COMPANY, INC.
Corporate Headquarters
15 Walker Ave.
Suite 101
Pikesville / Baltimore, MD 21208

info@greatercannabiscompany.com

The Greater Cannabis Company is a holding corp whose investment strategy is centered around the cannabis sector through direct investments, acquisitions, joint ventures and e-commerce.

Patent information:
Here is patent information:

https://patents.google.com/patent/WO2010135053A2/en?oq=Dual+and+single+layer+dosage
Inventor:
Hock Seng Tan
Siew Lian Chung

Original Assignee
Bionex Pharmaceuticals Llc
Priority date
2009-05-21
http://bionexpharma.com/Management.aspx

GCAN NEWS by Date:

October 21, 2019-
Former Portugal State Secretary of Health Joins Greater Cannabis Company’s European Partner, Symtomax

http://www.globenewswire.com/news-release/2019/10/21/1932612/0/en/Former-Portugal-State-Secretary-of-Health-Joins-Greater-Cannabis-Company-s-European-Partner-Symtomax.html?ev=1

October 15, 2019 - The Greater Cannabis Company Expands CBD Delivery Portfolio With Newly Developed Transdermal Patch
https://markets.businessinsider.com/news/stocks/the-greater-cannabis-company-expands-cbd-delivery-portfolio-with-newly-developed-transdermal-patch-1028599131

September 21, 2019 - GCAN CEO Aitan Zacharin to be interviewed on Yahoo Finance News
CEO will appear on the On The Move show to discuss Company’s technology as a high-tech alternative to vaping devices,
why the GCANRx patch is safer, and what’s in the pipeline for the future.
https://finance.yahoo.com/news/greater-cannabis-ceo-interviewed-today-125624622.html

https://finance.yahoo.com/video/gcanrx-offers-oral-patch-cannabinoid-170756517.html
 

September 19, 2019 - Corporate Update to Shareholders
http://www.globenewswire.com/news-release/2019/09/19/1918060/0/en/The-Greater-Cannabis-Company-Provides-Corporate-Update-to-Shareholders.html?ev=1

August 20, 2019 -Q2 Report SEC 10Q
https://www.sec.gov/Archives/edgar/data/1695473/000149315219012969/form10-q.htm

August 5, 2019 - PRE-14C
https://www.sec.gov/Archives/edgar/data/1695473/000149315219011598/formpre14c.htm

July 23, 2019 - Amended 10k/A
https://www.sec.gov/Archives/edgar/data/1695473/000149315219010967/form10-ka.htm

June 25, 2019 - Letter of Intent with RST, Inc
http://www.globenewswire.com/news-release/2019/06/25/1873932/0/en/Greater-Cannabis-Company-Signs-letter-of-intent-LOI-with-RST-Inc.html?ev=1

http://rstincbeauty.com/

May 20, 2019 - FORM 10-Q Report (Quarterly Financials)
https://www.sec.gov/Archives/edgar/data/1695473/000149315219007846/form10-q.htm

May 7, 2019 - GREATER CANNABIS COMPANY PARTNERS WITH SYMTOMAX®
TO EXPAND ACROSS EUROPE, THE MIDDLE EAST AND AFRICA


http://www.globenewswire.com/news-release/2019/05/07/1818383/0/en/GREATER-CANNABIS-COMPANY-PARTNERS-WITH-SYMTOMAX-TO-EXPAND-ACROSS-EUROPE-THE-MIDDLE-EAST-AND-AFRICA.html?ev=1

https://www.symtomax.com/

May 1, 2019 -CEO to Discuss Initial Stage of the Global Commercialization of His Company’s
Proprietary Cannabinoid Delivery System, which Resemble “LISTERINE’S POCKETPACKS®
http://www.globenewswire.com/news-release/2019/05/01/1813622/0/en/Greater-Cannabis-CEO-to-be-Interviewed-Today-By-Cheddar-Financial-News-Live-From-the-New-York-Stock-Exchange.html?ev=1

April 16, 2019 - GCAN Licenses CBD Patch Technology to
Majory Brazilian Retail Pharmacy Company

http://www.globenewswire.com/news-release/2019/04/16/1804688/0/en/GREATER-CANNABIS-COMPANY-LICENSES-CBD-PATCH-TECHNOLOGY-TO-MAJOR-BRAZILIAN-RETAIL-PHARMACY-COMPANY.html?ev=1

April 15, 2019 - SEC Update 10K
https://www.sec.gov/Archives/edgar/data/1695473/000149315219005257/form10-k.htm

April 11, 2019 - GCAN Partners with Allume Cosmeticos
to Develope New Cosmetics Line


http://www.allume.com.br/web/

https://www.otcmarkets.com/stock/GCAN/news/Greater-Cannabis-Company-Partners-with-Allume-Cosmeticos-To-Develop-New-Cosmetics-Line?id=224537

April 8, 2019 -GCAN Announces Expansion into CBD Cosmetic and Beauty Market
http://www.globenewswire.com/news-release/2019/04/09/1799720/0/en/Greater-Cannabis-Company-Announces-Expansion-Into-CBD-Cosmetics-And-Beauty-Market.html?ev=1

April 1, 2019 -Clinical Trials Begin
http://www.globenewswire.com/news-release/2019/04/01/1790833/0/en/GREATER-CANNABIS-TO-BEGIN-CLINICAL-STUDY-OF-CBD-ABSORPTION-THROUGH-ITS-MULTIFUNCTIONAL-MULTILAYER-INTRA-ORAL-DRUG-DELIVERY-TECHNOLOGY.html?ev=1

March 8, 2019 - 9,000,000 Prefered Shares AMENDMENT
http://search.sunbiz.org/Inquiry/CorporationSearch/ConvertTiffToPDF?storagePath=COR%5C2019%5C0313%5C24613995.Tif&documentNumber=P17000004537

February 27, 2019 - UPLISTING TO OTCQB COMPLETE
http://globenewswire.com/news-release/2019/02/27/1743521/0/en/The-Greater-Cannabis-Company-Announces-Uplisting-To-New-Market-Tier.html?ev=1

February 15, 2019 - SEC - 8K - Current Report
https://www.sec.gov/Archives/edgar/data/1695473/000149315219002166/form8-k.htm
Item 1.01 Entry into a Material Definitive Agreement.
Eagle Note

February 14, 2019 - FORM 8-A SEC Filed
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
https://www.sec.gov/Archives/edgar/data/1695473/000149315219002039/form8a-12g.htm

February 13, 2019 - OTCQB Certification Filed
https://backend.otcmarkets.com/otcapi/company/financial-report/211786/content

February 5, 2019 - OTCQB Certification filed
https://backend.otcmarkets.com/otcapi/company/financial-report/211467/content

January 28, 2019 - Annual Report (Florida) Filed
http://search.sunbiz.org/Inquiry/CorporationSearch/GetDocument?aggregateId=domp-p17000004537-69a1f1d7-2049-4ebf-bb2d-ecbb1559d26b&transactionId=p17000004537-2c800c85-d1af-438b-8bc1-d1c585105683&formatType=PDF

January 27, 2019 - Israel Gives Green Light to Medical Cannabis Exports
https://www.jpost.com/Israel-News/Israel-gives-green-light-to-medical-cannabis-exports-578815

January 25, 2019- OTCQB Certification
https://backend.otcmarkets.com/otcapi/company/financial-report/210982/content

January 23, 2019 - OTC MARKETS Registering to UPLIST OTCQB
https://backend.otcmarkets.com/otcapi/company/financial-report/210930/content

January 3, 2019 - FORM 3 Filed OTCMARKETS`
Benificial Ownership Registration

https://www.otcmarkets.com/filing/html?id=13165789&guid=GTRtUWzJqe9Gcth

January 7,2019 - World Wide Distribition Deal with Ican
https://www.israel-cannabis.com/

http://globenewswire.com/news-release/2019/01/07/1681268/0/en/The-Greater-Cannabis-Company-Announces-Distribution-Agreement-With-Leading-Global-Cannabis-Company-iCAN-Israel-Cannabis-Ltd.html?ev=1

November 19, 2018 - FORM 10 Q
https://www.sec.gov/Archives/edgar/data/1695473/000149315218016446/form10-q.htm

November 15, 2018 - 8K/8 Amendment No.1
https://www.sec.gov/Archives/edgar/data/1695473/000149315218016259/form8-ka.htm


 

   

November 2, 2018 - News Release
Innovative Cannabis Delivery Technologies on the Rise:
The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth
https://globenewswire.com/news-release/2018/11/02/1641958/0/en/Innovative-Cannabis-Delivery-Technologies-on-the-Rise-The-Greater-Cannabis-Company-Inc-OTC-GCAN-Aphria-Tilray-Aurora-and-Canopy-Growth.html

October 31, 2018 - News Release
The Greater Cannabis Company to Update Shareholders on Corporate Strategy and
Developments of Eluting Patch Platform (EPP) for Cannabinoid Use
https://globenewswire.com/news-release/2018/10/31/1640546/0/en/The-Greater-Cannabis-Company-to-Update-Shareholders-on-Corporate-Strategy-and-Developments-of-Eluting-Patch-Platform-EPP-for-Cannabinoid-Use.html

October 11, 2018 - The Greater Cannabis Company Files Additional Patent
to Further Protect Proprietary Cannabinoid Delivery System

http://www.globenewswire.com/news-release/2018/10/11/1620215/0/en/The-Greater-Cannabis-Company-Files-Additional-Patent-to-Further-Protect-Proprietary-Cannabinoid-Delivery-System.html

October 8, 2018 - New Corporate Website was launched
http://gcanrx.com/

October 4, 2018 - The Company Appoints Dr. Hock Tan as Chairman of Scientific Advisory Board
https://globenewswire.com/news-release/2018/10/04/1601401/0/en/The-Greater-Cannabis-Company-Appoints-Dr-Hock-Tan-as-Chairman-of-Scientific-Advisory-Board.html

September 26, 2018 - 8K filed with Sec
https://www.sec.gov/Archives/edgar/data/1695473/000149315218013804/form8-k.htm

September 24, 2018 - News Release

The Greater Cannabis Company Announces Appointment of David Tavor to its Board of Directors
https://www.otcmarkets.com/stock/GCAN/news/story?e&id=1178022

The Greater Cannabis Company Inc.

https://www.otcmarkets.com/stock/GCAN/security

http://www.nadental.com/index

https://www.focusglobalsupply.com/

http://www.pharmedica.co.il/default.as

 
PharMedica is a privately held company founded in 2008, specializing in the Biotech and Medical Device industries.The company developed an “Eluting Bandage Platform” - a multifunctional, multilayer, intra-oral drug delivery platform.This mucoadhesive film is applied on the internal mouthtissue. Firmly attached yet totally non-irritant, it disintegrates and dissolves as the treatment progresses.The Eluting Bandage Platform is aimed at two major markets: Oral-Care, and Trans-membrane Drug Delivery.

THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 21, 2018 (the “Effective Date”), by and between Pharmedica Ltd. an Israeli company (“Pharmedica”), and Green C Corporation a company incorporated under the laws of Canada with its principal place of business at 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8 (“Licensee”). Pharmedica and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties”.

Green C Corporation: 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8

Tel: 416-661-0728; Attn: Elisha Kalfa; E-mail: elisha@focusglobalsupply.com

Pharmedica: 9 Andre Saharov, Matam, Building #25, Haifa 508409, Tel: +(972) 04 8342155; Fax: +(972) 04 8341233 Attn: Dr. Yoram Rubin, CEO E-mail yrubin@pharmedica.co.il

with a copy (which shall not constitute notice) to: Tulchinsky Stern Marciano Cohen Levitski & Co., 4 Berkowitz Street, Museum Tower, 12th Floor, Tel-Aviv 6423806, Fax: +972-3-607-5050, Attn: Adv. Alon Tabak Aviram; Email: alont@tslaw.co.il.

 
 

Annex B – Patent(s)/Patent Application(s)

1. WO 2012/104834 A1

New oral dissolving films for insulin administration, for treating diabetes.

filed on December 2011. National Phase at Israel and the USA.

2. WO 2010/135053 A2

Dual and single layer dosage forms.

Issued USA patent on April 28, 2015.

3. PCT/IL 2017/050845

Adhesive Oral dissolved Films in Managing Oral Care.

PCT on 31 July 2017.

1

Annex C – Diligence Milestones

Licensee is required to meet the following development/regulatory/commercialization milestones in order to retain the license:

  ? Successful completion of the development of product samples by the end of year 1, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
     
  ? Successful completion of product scale-up and receipt of regulatory marketing approval by the end of year 3, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
     
  ? First commercial sale by the end of year 3 in any of the following territories: US, Canada, Japan, western Europe, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
     
  ? $50,000 in annual sales each year from years 5-9
     
  ? $100,000 in annual sales each year from year 10 onwards
     
     
     
     
     
     
     
     
     

 

 

________________________________________________________________________________________________________

August 20, 2018 - 10Q Edgar Search
https://www.sec.gov/Archives/edgar/data/1695473/000149315218012327/form10-q.htm

JULY 31, 2018 _ NEW OWNERSHIP LISTED ON 8k THIS COULD BE HUGE

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001695473&owner=include&count=40

As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board of Directors of the Company (the “Board”) appointed Aitan Zacharin as Director and Chief Executive Officer of the Company and Mark Radom as chief legal officer of the Company.

Mark Radom previously held the positions President, Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of Graphite Corp. Although there was no arrangement or understanding between Mark Radom and any other person(s) pursuant to which he was selected as chief legal officer of the Company, the Selling Shareholders decided on their own initiative to offer Mr. Radom the position of chief legal officer. Mark Radom has no family relationships with any director or executive officer of the Company, or persons nominated or chosen by the Company to become directors or executive officers. Furthermore, the Company is not aware of any transaction involving Mark Radom requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction.

The Board believes that Mr. Radom’s extensive experience in business development, management of complex projects and legal services in connection therewith will be invaluable in achieving the Company’s goals.

Professional History of Aitan Zacharin

Mr. Zacharin is an experienced executive with a broad knowledge in building and managing technology and consumer products businesses. In 2012, he co-founded Fuse Science, an innovative biotechnology company headquartered in Miami, Florida and Oxnard, California. Mr. Zacharin was responsible for the development and growth of the business from a seed stage R&D company to a publicly traded CPG and biotech business with multiple subsidiaries. During his tenure he was tasked with expanding the biotechnology IP portfolio, spearheading multiple in vitro studies, and growing the consumer products business. In scaling the company, Mr. Zacharin identified and hired executive talent to lead the commercialization strategy including the past President of SC Johnson Company and previous CEO of Champs and Footlocker Sports. He successfully led the company to raise over $10M in three over-subscribed rounds, as well as negotiated contracts with 26 world renowned athlete and celebrity brand ambassadors, which included top ranked pro golfer Tiger Woods. Under Mr. Zacharin’s leadership the company developed and commercialized multi-category consumer products through a retail footprint of 15,000 doors. Since his exit from Fuse Science, he has been advising and investing in mid to late stage technology startups, and assisting them with capitalization, business strategy and development, and accelerating growth. Mr. Zacharin holds dual degrees from the University of South Florida in Tampa Bay. He resides in Baltimore, Maryland, and maintains various board appointments both professionally and philanthropically.

Professional History of Mark Radom

From August 2015 to July 2018, Mr. Radom served as chief executive officer of Graphite Corp. From February 2010 through July 2015, Mr. Radom served as the chief carbon officer and general counsel of Blue Sphere Corporation. From 2009 through 2010, Mr. Radom was managing director of Carbon MPV Limited, a Cyprus company focused on developing renewable energy and carbon credit projects. From 2007 to 2009, Mr. Radom was general counsel and chief operating officer of Carbon Markets Global Limited, a London-based carbon credit and renewable energy project developer. Mr. Radom has extensive experience in business development in the renewable energy and carbon credit sectors. He has sourced over U.S. $100,000,000 in renewable energy, industrial gas and carbon credit projects and managed many complex aspects of their implementation. He was legal counsel for a number of carbon and ecological project developers and was responsible for structuring joint ventures and advising on developing projects through the CDM/JI registration cycle and emission reduction purchase agreements under the auspices of the Kyoto Protocol. Prior to this, he worked on Wall Street and in the City of London as a US securities and capital markets lawyer where he represented sovereigns, global investment banks and fortune 500 companies across a broad range of capital raising and corporate transactions. He is a graduate of Duke University and Brooklyn Law School. Mr. Radom is admitted to practice law in New York and New Jersey and speaks fluent Russ

     

(d)       Appointment of Directors

As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board appointed Aitan Zacharin as a director of the Company. Mr. Zacharin does not have any family relationships with any other executive officers or directors of the Company, or persons nominated or chosen by the Company to become directors or executive officers. There is no arrangement or understanding pursuant to which Mr. Zacharin was appointed as a member of the Board. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction. It is contemplated that Mr. Zacharin may serve on certain committees of the Board, but no such committee appointments have been made at this time.

Here's something more:

https://www.sec.gov/Archives/edgar/data/1695473/000149315218010899/form8-k.htm

This document shows it dated at the bottom left.

https://www.sec.gov/Archives/edgar/data/1695473/000149315218010899/ex2-1.htm

July 10, 2018 - SEC Edgar Search GCAN EFFECTIVE

https://www.sec.gov/Archives/edgar/data/1695473/999999999518001730/9999999995-18-001730-index.htm

July 9, 2018 - GCAN ADDED and to be TRADING THIS WEEK
FINRA DAILY LIST

Details

  Current Value
Daily List Date/Time 07/09/2018 12:02:54
Event Type Addition
Effective/Ex Date/Time 07/09/2018 00:00:00
Issue Type  
Symbol GCAN
Issue Name Greater Cannabis Co Inc Common Stock
Class  
ADR Ratio  
Maturity Date  
Market Category Other OTC
Offering Type No Restrictions
OATS Reportable (Rptbl) Flag Yes
Unit of Trade 100
Reg Fee Flag Yes
Daily List Comment  
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
07/09/2018 12:02:54 Addition 07/09/2018 00:00:00 GCAN Greater Cannabis Co Inc Common Stock Other OTC
GCAN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GCAN News: Quarterly Report (10-q) 08/19/2019 11:51:28 AM
GCAN News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/13/2019 01:40:58 PM
GCAN News: Proxy Statement - Other Information (preliminary) (pre 14c) 08/05/2019 03:47:30 PM
GCAN News: Amended Annual Report (10-k/a) 07/23/2019 12:14:54 PM
GCAN News: Quarterly Report (10-q) 05/20/2019 03:11:11 PM
PostSubject
#26408  Sticky Note https://www.healtheuropa.eu/symtomax-the-medical-cannabis-company-leading-the-fi Dr. Gwinis 10/17/19 08:19:51 AM
#26275  Sticky Note Share Structure Update: Sprycel 10/16/19 06:57:07 AM
#24094  Sticky Note September 12, 2019 No-Quarter 09/03/19 11:20:48 AM
#22712  Sticky Note They received $62.5K from EMET and paid them Fuzzy Bunny 07/27/19 11:15:47 AM
#26865   Hear's sumting else to say: ROTFLMAO! downandoutthanksd 10/22/19 12:19:24 AM
#26864   Great article!!! Secret Service 10/21/19 10:27:20 PM
#26863   Did I not say 2 weeks ago when Sprycel 10/21/19 09:27:33 PM
#26862   The sooner we get rid of Wayne the Sprycel 10/21/19 09:13:11 PM
#26861   The sooner the better to get him to Secret Service 10/21/19 09:10:54 PM
#26860   Until they convert it is a mute point! Sprycel 10/21/19 09:04:23 PM
#26859   It’s good to see you here PM. Thoughts Secret Service 10/21/19 09:03:45 PM
#26858   Problem is, he needs the money NOW for Sprycel 10/21/19 08:58:49 PM
#26857   This all makes sense and thank you for Secret Service 10/21/19 08:57:10 PM
#26856   This goes all the way back to GCAN Fuzzy Bunny 10/21/19 08:53:48 PM
#26855   Just some facts from the last 27 minutes Sprycel 10/21/19 08:42:31 PM
#26854   GCAN AND MONDAY NIGHT FOOTBALL ARE 2 WINNERS! Sprycel 10/21/19 08:28:48 PM
#26853   Here's something else to say: Fuzzy Bunny 10/21/19 08:27:41 PM
#26852   This goes back to the days of NO Sprycel 10/21/19 08:26:35 PM
#26851   No they get the common stock at the Sprycel 10/21/19 08:25:30 PM
#26850   Free ..... actually less than free. They Fuzzy Bunny 10/21/19 08:23:24 PM
#26849   They did not get them for free. In Sprycel 10/21/19 08:21:07 PM
#26848   Okay this one confuses me! I thought Sprycel 10/21/19 08:19:46 PM
#26847   Ahhhhh, I see....so they did or didn't get Fuzzy Bunny 10/21/19 08:17:52 PM
#26846   They got 9 million Preferred B shares which Sprycel 10/21/19 08:15:07 PM
#26845   Link please to that CD because all of Sprycel 10/21/19 08:11:38 PM
#26844   Lets not forget the tdameritrade shares for sell abe01 10/21/19 08:10:22 PM
#26843   all of EMET's CD's were paid off on Fuzzy Bunny 10/21/19 08:09:19 PM
#26842   Link please to that CD because all of Sprycel 10/21/19 08:07:57 PM
#26841   Lets take Oct 3, 2018 for one example. Fuzzy Bunny 10/21/19 08:05:15 PM
#26840   Just ask for a link to the CD Sprycel 10/21/19 07:58:52 PM
#26839   False! No Support for that statement Plowmaster 10/21/19 07:56:45 PM
#26838   Nope, just asking for a proof of a Sprycel 10/21/19 07:53:19 PM
#26837   So you are thinking maybe 75%? Fuzzy Bunny 10/21/19 07:50:32 PM
#26836   I would love to see a link to Sprycel 10/21/19 07:48:22 PM
#26835   Yep....almost everyone losing here......we know it is bad Fuzzy Bunny 10/21/19 07:47:01 PM
#26834   EMET owns about 1 million shares at they Sprycel 10/21/19 07:45:04 PM
#26833   Ahhhhh.....so the claim that Wayne was selling his Fuzzy Bunny 10/21/19 07:40:50 PM
#26832   Last report he owns 6 million shares free Sprycel 10/21/19 07:35:36 PM
#26831   How many shares does Sylios ( Wayne ) Secret Service 10/21/19 07:34:09 PM
#26830   That was the funniest post all day! Sprycel 10/21/19 07:33:27 PM
#26829   Why would Wayne sell his personal shares instead Fuzzy Bunny 10/21/19 07:31:18 PM
#26828   UMMMM............to get the cash to pay for UNGS Sprycel 10/21/19 07:28:30 PM
#26827   That would be stupid if true. Why Fuzzy Bunny 10/21/19 07:26:10 PM
#26826   Update on Share Structure. The T/A is Sprycel 10/21/19 07:26:04 PM
#26825   Reverse again? ?? So do two reverses JJ100 10/21/19 07:18:30 PM
#26824   If you want to steal Wayne's shares, that Sprycel 10/21/19 06:56:34 PM
#26823   Looks like this thing reverted to the form GreedyAgorist 10/21/19 06:41:50 PM
#26822   800,000 shares @.055 vs buying at .13 = Releasemas 10/21/19 06:41:48 PM
#26821   They may have to do a Reverse split Fuzzy Bunny 10/21/19 06:35:34 PM
#26820   Yup another red day heading to subs. rottweiller 10/21/19 06:30:37 PM
#26819   Wasn't i reading posts last week about the rottweiller 10/21/19 06:27:30 PM
#26818   How about each non-filing? Fuzzy Bunny 10/21/19 06:27:29 PM
#26817   Can't have your cake at eat it to! Sprycel 10/21/19 06:26:30 PM
#26816   Yes, if they are a SEC reporting Fuzzy Bunny 10/21/19 06:24:42 PM
PostSubject